Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 9, 1, 20, 10 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 6, 7, 1, 5 and 3 molecules, respectively.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 5
Cytomegalovirus (HHV-5) Infections - Overview 6
Cytomegalovirus (HHV-5) Infections - Therapeutics Development 7
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 21
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 29
Cytomegalovirus (HHV-5) Infections - Drug Profiles 41
Cytomegalovirus (HHV-5) Infections - Dormant Projects 148
Cytomegalovirus (HHV-5) Infections - Discontinued Products 152
Cytomegalovirus (HHV-5) Infections - Product Development Milestones 153
Appendix 161

List Of Tables

List of Tables
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2018 15
Number of Products under Development by Companies, H1 2018 17
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 18
Number of Products under Development by Universities/Institutes, H1 2018 20
Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018 21
Products under Development by Companies, H1 2018 22
Products under Development by Companies, H1 2018 (Contd..1), H1 2018 23
Products under Development by Companies, H1 2018 (Contd..2), H1 2018 24
Products under Development by Companies, H1 2018 (Contd..3), H1 2018 25
Products under Development by Universities/Institutes, H1 2018 26
Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018 28
Number of Products by Stage and Target, H1 2018 30
Number of Products by Stage and Mechanism of Action, H1 2018 32
Number of Products by Stage and Route of Administration, H1 2018 34
Number of Products by Stage and Molecule Type, H1 2018 36
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H1 2018 37
Cytomegalovirus (HHV-5) Infections - Pipeline by AlfaSigma SpA, H1 2018 37
Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H1 2018 38
Cytomegalovirus (HHV-5) Infections - Pipeline by AvidBiotics Corp, H1 2018 38
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2018 38
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix Inc, H1 2018 39
Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Inc, H1 2018 40
Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax BV, H1 2018 40
Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H1 2018 41
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H1 2018 41
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H1 2018 41
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H1 2018 42
Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea SA, H1 2018 42
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H1 2018 43
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H1 2018 43
Cytomegalovirus (HHV-5) Infections - Pipeline by Moderna Therapeutics Inc, H1 2018 44
Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2018 44
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H1 2018 44
Cytomegalovirus (HHV-5) Infections - Pipeline by Qurient Co Ltd, H1 2018 45
Cytomegalovirus (HHV-5) Infections - Pipeline by Shire Plc, H1 2018 45
Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H1 2018 46
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H1 2018 46
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2018 47
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H1 2018 47
Cytomegalovirus (HHV-5) Infections - Pipeline by Vectorite Biomedical Inc, H1 2018 47
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Inc, H1 2018 48
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 156
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018 157
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 (Contd..2), H1 2018 158
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 (Contd..3), H1 2018 159
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2018 160

List Of Figures

List of Figures
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2018 15
Number of Products under Development by Companies, H1 2018 16
Number of Products under Development by Universities/Institutes, H1 2018 19
Number of Products by Top 10 Targets, H1 2018 29
Number of Products by Stage and Top 10 Targets, H1 2018 29
Number of Products by Top 10 Mechanism of Actions, H1 2018 31
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 31
Number of Products by Routes of Administration, H1 2018 33
Number of Products by Stage and Routes of Administration, H1 2018 33
Number of Products by Top 10 Molecule Types, H1 2018 35
Number of Products by Stage and Top 10 Molecule Types, H1 2018 35

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2018

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2018According to the recently published report Human cytomegalovirus 65

USD 3500 View Report

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027Cytomegalovirus (CMV) is a human herpesvirus (HHV-5) of the herpesviridae family. Exposure to the virus can result in lytic infection, producing symptoms

USD 10995 View Report

Cytomegalovirus (HHV-5) Infections - Pipeline Insight, 2018

Cytomegalovirus (HHV-5) Infections - Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Cytomegalovirus (HHV-5) Infections development. The report

USD 1250 View Report

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2017

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2017, provides an overview of the

USD 2000 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available